Resources

February 06, 2023

White paper: A proprietary mammalian suspension technology for scalable rAAV production: The Pro10™ cell line

Discover how the HEK293-derived Pro10™ cell line accelerates AAV vector production. This whitepaper explores a scalable, animal component-free platform that reduces process development time and costs, meeting growing clinical and commercial demands for gene therapies.

Download

Explore more

Resources

Webinar: Exploring key regulatory considerations to ensure patient safety in the gene therapy space

In July, a panel of expert speakers—Christine Lebec (Sensorion), Leigh Shaw (SpliceBio), Nathalie Clement (Siren Biotechnology), and María Orío (Viralgen)—came together to explore the evolving regulatory landscape in the cell and gene therapy (CGT)...

July 09, 2025

News

Viralgen Joins Orphan Therapeutics Accelerator Clinical Development Network as a Manufacturing Partner to Advance Rare Disease Therapies

Viralgen brings strong AAV gene therapy manufacturing capabilities to growing group of partners supporting new model for developing and commercializing orphan drugs Boston, MA & San Sebastian, Spain - May 14, 2025 – Orphan Therapeutics Accelerator...

Resources

White paper: A proprietary mammalian suspension technology for scalable rAAV production: The Pro10™ cell line

VIRALGEN BUILDING 1

VIRALGEN BUILDING 2

WHO WE ARE

WHAT WE DO

EXPERT INSIGHTS

CAREERS

CONTACT US

Policies